Drug Discovery World

APRIL 3, 2023

As life science operates globally, the vision for the business was always to bring aptamers as an antibody alternative to researchers worldwide. What advice would you offer to similar start-ups?    AT: Integral to Aptamer Group’s offering is an in-depth understanding of molecular science.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. These efforts, along with many others, are opening doors for new possibilities in translational medicine.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers. This continues to be the standard of care.

Research 52

Research In-Vitro In-Vivo Development 52

XTalks

OCTOBER 1, 2020

A life-changing moment came for Dr. Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. The journey first starts with the decision to make the switch. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

Drug Discovery World

OCTOBER 20, 2022

Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. Fibroblasts in the tumour microenvironment. This is of particular importance in dense tissues like breast and pancreas.

Antibody 52

Antibody In-Vivo Life Science Development 52